• 1 Department of Internal Medicine, Kangbuk Samsung Hospital Sungkyunkwan University, Seoul, Korea
  • 2 The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
  • 3 Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
  • 4 Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
  • 5 Gleneagles Medical Centre and Duke-NUS Medical School, Singapore
  • 6 Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan
  • 7 Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India
  • 8 Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 9 Department of Internal Medicine, Korea University, Seoul, Korea
  • 10 Department of Internal Medicine, Hanyang University Guri Hospital, Seoul, Gyunggi, Korea
  • 11 Department of Internal Medicine, Kyung Hee University, Seoul, Korea
  • 12 Department of Gastroenterology, Shanghai Jiao Tong University, Shanghai, China
  • 13 Department of Gastroenterology, Fourth Military Medical University, Xi'an, China
  • 14 Department of Gastroenterology, Peking Union Medical College, Beijing, China
  • 15 Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
  • 16 Department of Gastroenterology, Shiga University, Otsu, Japan
  • 17 Department of Internal Medicine, Toho University, Sakura, Japan
  • 18 Department of Medicine, Jichi Medical University, Tochigi, Japan
  • 19 Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan
  • 20 Department of Gastroenterology, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India
  • 21 Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
J Gastroenterol Hepatol, 2018 Jan;33(1):30-36.
PMID: 29024102 DOI: 10.1111/jgh.14018


Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised three parts: (3) management of latent TB in preparation for anti-TNF therapy, (4) monitoring during anti-TNF therapy, and (5) management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications